<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445613</url>
  </required_header>
  <id_info>
    <org_study_id>10-720</org_study_id>
    <nct_id>NCT01445613</nct_id>
  </id_info>
  <brief_title>Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy</brief_title>
  <acronym>CANOPY</acronym>
  <official_title>CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the CANOPY trial is to assess the continued safety and effectiveness of the
      RX Acculink Carotid Stent System under commercial use in subjects at standard risk for
      adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of
      carotid stenting experience.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days)</measure>
    <time_frame>0 to 365 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Between 31 and 365 Days</measure>
    <time_frame>365 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death and All Stroke</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Peri-procedural Death and Stroke by Symptomatic Status</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Symptomatic Status</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Peri-procedural Death and Stroke by Age</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Age</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Driven Target Lesion Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Driven Target Lesion Revascularization</measure>
    <time_frame>180 days</time_frame>
    <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Driven Target Lesion Revascularization</measure>
    <time_frame>365 days</time_frame>
    <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical success is defined as the attainment of &lt; 50% residual stenosis of the target lesion and absence of a death or stroke 30-day post-procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1203</enrollment>
  <condition>Carotid Artery Disease</condition>
  <condition>Stroke</condition>
  <condition>Amaurosis Fugax</condition>
  <condition>Transient Ischemic Attack (TIA)</condition>
  <arm_group>
    <arm_group_label>RX Acculink Carotid Stent System (RX Acculink)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RX Acculink Carotid Stent System (RX Acculink)</intervention_name>
    <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
    <arm_group_label>RX Acculink Carotid Stent System (RX Acculink)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be ≥ 18 years of age.

          2. Subject does not have any condition that limits their anticipated survival to less
             than 3 years.

          3. Subject or a legally authorized representative must provide written informed consent
             prior to any trial related procedure.

          4. Subjects with neurological symptoms within 180 days of the procedure and ≥ 70%
             stenosis of the common or internal carotid artery by ultrasound or ≥ 50% stenosis of
             the common or internal carotid artery by angiogram - OR-

          5. Subjects without neurological symptoms within 180 days of the procedure and ≥ 70%
             stenosis of the common or internal carotid artery by ultrasound or ≥ 60% stenosis of
             the common or internal carotid artery by angiogram.

          6. Subject with all the following target vessel characteristics:

               1. Discrete lesion in internal carotid artery (ICA) with or without involvement of
                  the contiguous common carotid artery (CCA).

               2. Vessel diameter ≥ 4.0 mm and ≤ 9.0 mm from reference or contralateral artery.

               3. Absence of excessive vessel tortuosity that would impede delivery of devices.

          7. Subject must agree not to participate in any other clinical trial for a period of 1
             year following the index procedure.

        Exclusion Criteria:

          1. Subjects with anatomic or clinical conditions which make them at high risk for adverse
             events from carotid endarterectomy (CEA).

          2. Subject with Hgb &lt;10.g/dl or platelet count &lt; 125,000 µl or has heparin-associated
             thrombocytopenia. For subjects on Coumadin (Warfarin) and for subjects with a platelet
             or coagulation disorder: Has an international normalized ratio (INR) &gt; 1.5.

          3. Subject has active bleeding diathesis or coagulopathy or subject would refuse blood
             transfusions.

          4. Subject is currently on a list for major organ transplantation (i.e., heart, lung,
             liver, kidney) or is being evaluated for such.

          5. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint.

          6. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to the index procedure per site
             standard test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Christopher Metzger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellmont Holston Valley Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Vascular</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <results_first_submitted>December 3, 2015</results_first_submitted>
  <results_first_submitted_qc>March 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2016</results_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carotid</keyword>
  <keyword>Stent</keyword>
  <keyword>Carotid Endarterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Amaurosis Fugax</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment for the CANOPY clinical trial started on October 11, 2011 and was completed on September 12, 2013. The enrollment goal (1200 subjects) was reached with a total of 1203 subjects enrolled at 97 clinical sites.</recruitment_details>
      <pre_assignment_details>3/1203 subjects who received a non-study stent, were excluded from the analysis. A total of 1200 subjects were included in the primary analysis population (Full analysis set (FAS)).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RX Acculink Carotid Stent System (RX Acculink)</title>
          <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>30-day Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1-year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1088"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received a non-study stent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RX Acculink Carotid Stent System (RX Acculink)</title>
          <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.52" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refused to answer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Information not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days)</title>
        <time_frame>0 to 365 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>RX Acculink Carotid Stent System (RX Acculink)</title>
            <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days)</title>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and All Stroke</title>
        <time_frame>30 Days</time_frame>
        <population>FAS population. The number of participants analyzed includes subjects with data available at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Acculink Carotid Stent System (RX Acculink)</title>
            <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
          </group>
        </group_list>
        <measure>
          <title>Death and All Stroke</title>
          <population>FAS population. The number of participants analyzed includes subjects with data available at that time frame.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.44" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Between 31 and 365 Days</title>
        <time_frame>365 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>RX Acculink Carotid Stent System (RX Acculink)</title>
            <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Between 31 and 365 Days</title>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Peri-procedural Death and Stroke by Symptomatic Status</title>
        <time_frame>30 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>Composite of Peri-procedural DS in the Symptomatic Group</title>
            <description>Symptomatic subject: Subject with Amaurosis Fugax (a temporary (≤10 minutes) loss of vision in one eye due to insufficient blood flow to the retina), stroke or transient ischemic attack (TIA) (hemispheric or ocular) in the hemisphere supplied by the target vessel in the last 180-days prior to procedure.</description>
          </group>
          <group group_id="O2">
            <title>Composite of Peri-procedural DS in the Asymptomatic Group</title>
            <description>Asymptomatic Subject: Subject does not have a history of symptoms, stroke or TIA (hemispheric or ocular/Amaurosis Fugax) in the hemisphere supplied by the target vessel in the last 180 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Peri-procedural Death and Stroke by Symptomatic Status</title>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="865"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="3.55" upper_limit="8.95"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.53" upper_limit="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Symptomatic Status</title>
        <time_frame>365 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>In Symptomatic Group</title>
            <description>Symptomatic subject: Subject with Amaurosis Fugax (a temporary (≤10 minutes) loss of vision in one eye due to insufficient blood flow to the retina), stroke or TIA (hemispheric or ocular) in the hemisphere supplied by the target vessel in the last 180-days prior to procedure.</description>
          </group>
          <group group_id="O2">
            <title>In Asymptomatic Group</title>
            <description>Asymptomatic Subject: Subject does not have a history of symptoms, stroke or TIA (hemispheric or ocular/Amaurosis Fugax) in the hemisphere supplied by the target vessel in the last 180 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Symptomatic Status</title>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="865"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5"/>
                    <measurement group_id="O2" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Peri-procedural Death and Stroke by Age</title>
        <time_frame>30 days</time_frame>
        <population>FAS population. The number of participants analyzed includes subjects with data available at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>In Octogenarian Group</title>
            <description>Octogenarian: A person with age &gt;= 80 years.</description>
          </group>
          <group group_id="O2">
            <title>In Non-octogenarian Group</title>
            <description>Non-octogenarian: A person who is less than 80 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Peri-procedural Death and Stroke by Age</title>
          <population>FAS population. The number of participants analyzed includes subjects with data available at that time frame.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="1062"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.95" upper_limit="8.59"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.39" upper_limit="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Age</title>
        <time_frame>365 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>In Octogenarian Group</title>
            <description>Octogenarian: A person with age &gt;= 80 years.</description>
          </group>
          <group group_id="O2">
            <title>In Non-octogenarian Group</title>
            <description>Non-octogenarian: A person who is less than 80 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Age</title>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="1082"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Driven Target Lesion Revascularization</title>
        <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
        <time_frame>30 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>RX Acculink Carotid Stent System (RX Acculink)</title>
            <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Driven Target Lesion Revascularization</title>
          <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Driven Target Lesion Revascularization</title>
        <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
        <time_frame>180 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>RX Acculink Carotid Stent System (RX Acculink)</title>
            <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Driven Target Lesion Revascularization</title>
          <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Driven Target Lesion Revascularization</title>
        <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
        <time_frame>365 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>RX Acculink Carotid Stent System (RX Acculink)</title>
            <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Driven Target Lesion Revascularization</title>
          <description>Target Lesion Revascularization (TLR) is designated as clinically driven if the subject has recurring symptoms or has become newly symptomatic and has stenosis &gt;50% in the stented lesion, or is asymptomatic and has a stenosis of &gt;80% in the stented lesion.</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>Clinical success is defined as the attainment of &lt; 50% residual stenosis of the target lesion and absence of a death or stroke 30-day post-procedure.</description>
        <time_frame>30 days</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>RX Acculink Carotid Stent System (RX Acculink)</title>
            <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Clinical success is defined as the attainment of &lt; 50% residual stenosis of the target lesion and absence of a death or stroke 30-day post-procedure.</description>
          <population>FAS population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="95.2" upper_limit="97.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>365 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RX Acculink Carotid Stent System (RX Acculink)</title>
          <description>Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
RX Acculink Carotid Stent System (RX Acculink): Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Abbott categories</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Arrhythmia (Includes Brady And Tachy)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Coronary artery disease - Coronary stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction - Non Q wave</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction - Q wave</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction - Unknown</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Surgery/Intervention Procedure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Infection At Insertion Site</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other: under access site complication</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other: under miscellaneous category</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Arrhythmia (Includes Brady And Tachy)</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Incisional Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Infection At Insertion Site</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>No reflow</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain At Insertion Site</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Transient Ischemia Attack</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vessel Trauma</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Viral, Bacterial And Fungal Infections</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction To Contrast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Wound Complication Or Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Sensory Deficit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Surgery/Intervention Procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Delerium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Mental Status Change</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Post Traumatic Hemorrage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Speech Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Transient Ischemia Attack</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Visual Disturbances</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Kidney Damage Due To Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Renal Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Surgery/Intervention Procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Urinary Retension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident - Major Hemorrhagic Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Major Hemorrhagic Non-Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Major Ischemic Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Major Ischemic Non-Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Minor Hemorrhagic Bilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Minor Hemorrhagic Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Minor Hemorrhagic Non-Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Minor Ischemic Bilateral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Minor Ischemic Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - Minor Ischemic Non-Ispilateral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Peripheral artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Abbott categories</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="619" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Ecchymosis/Bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>Blood Dyscrasia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Arrhythmia (Includes Brady And Tachy)</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>CAD - Coronary stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction - Non Q wave</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction - Q wave</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction - Unknown</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease (PVD)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Surgery/Intervention Procedure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease (GERD)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Gastrointestinal (GI) bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia (Includes Brady And Tachy)</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Ecchymosis/Bruising</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Infection At Insertion Site</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain At Insertion Site</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Edema (Non Pulmonary)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Access site event</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Allergic Reaction To Contrast</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Ecchymosis/Bruising</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Eye</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Incisional Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Infection At Insertion Site</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Jaw Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Mental Status Change</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>No reflow</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Oozing</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain At Insertion Site</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Speech Disturbance</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Transient Ischemia Attack</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Urinary Retension</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vasovagal</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vessel Trauma</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Viral, Bacterial And Fungal Infections</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Visual Disturbances</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction To Contrast</sub_title>
                <description>Allergic Reaction</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Allergic Reaction</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Allergic Reaction</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Viral, Bacterial And Fungal Infections</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Wound Complication Or Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Sensory Deficit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Surgery/Intervention Procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Delerium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Mental Status Change</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Post Traumatic Hemorrage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Sensory Deficit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Speech Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Transient Ischemia Attack</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Visual Disturbances</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Test</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Kidney Damage Due To Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Renal Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Surgery/Intervention Procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Urinary Retension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Viral, Bacterial And Fungal Infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Viral, Bacterial And Fungal Infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Major Hemorrhagic Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA)-Major Hemorrhagic Non-Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Major Ischemic Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Major Ischemic Non-Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Minor Hemorrhagic Bilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Minor Hemorrhagic Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Minor Hemorrhagic Non-Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Minor Ischemic Bilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Minor Ischemic Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA) - Minor Ischemic Non-Ispilateral</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Arrhythmia (Includes Brady And Tachy)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Deep venous thrombosis (DVT)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Peripheral artery disease (PAD)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease (PVD)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Surgery/Intervention Procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1200"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David R Rutledge</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>(408) 845-3820</phone>
      <email>david.rutledge@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

